Differential diagnosis of myasthenia gravis: A review.

Okeafor CU1*, Awoyesuku EA2
1Neuropsychiatry Unit, Department of Mental Health, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria.
2Department of Ophthalmology, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria.
*Correspondence: Dr. Chukwuma U Okeafor; +234 909 802 9963; chukwuma.okeafor@uniport.edu.ng

Download full article in pdf format


Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that is characterised by fatigable weakness of voluntary muscles. It is an auto immune disorder hitherto thought to be rare in our environment.
Aim: This paper aims to discuss the differential diagnosis of MG and increase the index of suspicion for these cases aiding early diagnosis.
Materials and Methods: Literature search was done using PubMed, ScienceDirect and Google scholar searches.
Conclusion: Myasthenia Gravis as an autoimmune and acquired condition manifests with various patterns of fatigable skeletal muscle weakness ranging from ocular to generalised distribution. A variety of clinical conditions that affect skeletal muscles could present as diagnostic challenges in Myasthenia Gravis. It is therefore necessary that the distinguishing clinical features and differentiating investigations in these other conditions should be borne in mind when assessing patients with muscular weakness

Keywords: Differential diagnosis, Myasthenia gravis.

Cite this article: Okeafor CU, Awoyesuku EA. Differential diagnosis of myasthenia gravis: A review. Yen Med J. 2020;2(2):5–14.


  1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475-490.
  2. Thomann KH, Pandya, S. Myasthenia gravis: Pathophysiology, diagnosis, differential diagnosis and management. Clin Eye Vis Care. 1995;7(1):3-13.
  3. Hirsch NP. Myasthenia gravis. Lecture notes Msc Clinical Neurology, Institute of Neurology, UCL. London. 2011
  4. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141-149.
  5. Hirsch NP. Neuromuscular junction in health and disease. Br J Anaesth. 2007;99(1):132-138.
  6. Meriggioli MN. Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci. 2009;26:94-108.
  7. Sahashi K, Engel AG, Linstrom JM, Lambert EH, Lennon VA. Ultrastructural localization of immune complexes (igG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol. 1978;37(2):212-223.
  8. Heinemann S, Bevan S, Kullberg R, Lindstrom J, Rice J. Modulation of acetylcholine receptor by antibody against the receptor. Proc Natl Acad Sci U S A. 1977;74(7):3090-3094.
  9. Burges J, Wray DW, Pizzighella S, Hall Z, Vincent A. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve. 1990;13(5):407-413.
  10. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, et al. Detection and characterization of musk antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55(4):580-584.
  11. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, et al. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain. 2008;131(Pt 7):1940-1952.
  12. Strobel P, Rosenwald A, Beyersdorf N, Kerkau T, Elert O, Murumagi A, et al. Selective loss of regulatory t cells in thymomas. Ann Neurol. 2004;56(6):901-904.
  13. Barnes PR, Kanabar DJ, Brueton L, Newsom-Davis J, Huson SM, Mann NP, et al. Recurrent congenital arthrogryposis leading to a diagnosis of myasthenia gravis in an initially asymptomatic mother. Neuromuscul Disord. 1995;5(1):59-65.
  14. Singman EL, Matta NS, Silbert DI. Use of the cogan lid twitch to identify myasthenia gravis. J Neuroophthal. 2011;31(3):239-240.
  15. Odel JG, Winterkorn JM, Behrens MM. The sleep test for myasthenia gravis. A safe alternative to tensilon. J Clin Neuroophthalmol. 1991;11(4):288-292.
  16. Seybold ME. The office tensilon test for ocular myasthenia gravis. Arch Neurol. 1986;43(8):842-843.
  17. Osserman KE, Kaplan LI. Rapid diagnostic test for myasthenia gravis: increased muscle strength, without fasciculations, after intravenous administration of edrophonium (tensilon) chloride. J Am Med Assoc. 1952;150(4):265-268.
  18. Nicholson GA, McLeod JG, Griffiths LR. Comparison of diagnostic tests in myasthenia gravis. Clin Exp Neurol. 1983;19:45-49.
  19. Lindstrom J. Immunological studies of acetylcholine receptors. J Supramol Struct. 1976;4(3):389-403.
  20. Lunn M, Hanna M, Howard R, Parton M, Reilly M. Nerve and muscle diseases. In: Clarke C, Howard R, Rossor M, Shorvon S, eds. Neurology: A Queen Square Textbook. West Sussex, UK: John Wiley & Sons; 2009:337-410.
  21. Muradyan N, Klissurski M, Alexandrov AS, Ishpekova B. Repetitive nerve stimulation of accessory nerve in diagnostic assessment of patients with myasthenia gravis. C. R. Acad. Bulg. Sci. 2012;65(3):411-418.
  22. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357(9274):2122-2128.
  23. Fukunaga H, Engel, A. G., Osame, M., and Lambert, E. H. Paucity and disorganization of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1982;5(9):686-697.
  24. Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902-908.
  25. O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111( Pt 3):577-596.
  26. Titulaer MJ, lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
  27. Rudnicki SA. Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology. 2007;68(21):1863-1864.
  28. Titulaer MJ, Wirtz PW, Wintzen AR, Verschuuren JJ. Re: Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology. 2008;70(1):86; author reply 86-87.
  29. Lorenzoni PJ, Scola RH, Kay CS, Parolin SF, Werneck LC. Non-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases. Arq Neuropsiquiatr. 2010;68(6):849-854.
  30. Titulaer MJ, Wirtz PW, Kuks JB, al. e. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol. 2008;201-202:153-158.
  31. Wirtz PW, Sotodeh M, Nijnuis M, Van Doorn PA, Van Engelen BG, Hintzen RQ, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2002;73(6):766-768.
  32. AAEM Quality Assurance Committee. Practice parameter for repetitive nerve stimulation and single fiber emg evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve. 2001;24(9):1236-1238.
  33. Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2005;32(4):515-520.
  34. Lecky BR. Transient neonatal Lambert-Eaton syndrome. J Neurol Neurosurg Psychiatry. 2006;77(9):1094.
  35. Komai K, Iwasa K, Takamori M. Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats. J Neurol Sci. 1999;166(2):126-130.
  36. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276-4281.
  37. Horowitz BZ. Botulinum toxin. Crit Care Clin. 2005;21(4):825-839.
  38. Werner SB, Chin J. Botulism-diagnosis, management and public health considerations. Calif. Med. 1973;118(5):84-88.
  39. Fox CK, Keet CA, Strober JB. Recent advances in infant botulism. Pediatr Neurol. 2005;32(3):149-154.
  40. Witoonpanich R, Vichayanrat E, Tantisiriwit K, Rattanasiri S, Ingsathit A. Electrodiagnosis of botulism and clinico-electrophysiological correlation. Clin Neurophysiol. 2009; 120(6):1135-1138.
  41. Nogajski JH, Kiernan MC, Ouvrier RA, Andrews PI. Congenital myasthenic syndromes. J Clin Neurosci. 2009;16(1):1-11.
  42. Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord. 2012;22(2):99-111.
  43. Ohno K, Engel AG. Congenital myasthenic syndromes: gene mutations. Neuromuscul Disord. 2004; 14(1):117-122.
  44. Bundey S. A genetic study of infantile and juvenile myasthenia gravis. J Neurol Neurosurg Psychiatry. 1972;35(1):41-51.
  45. Banwell BL, Russel J, Fukudome T, Shen XM, Stilling G, Engel AG. Myopathy, myasthenic syndrome, and epidermolysis bullosa simplex due to plectin deficiency. J Neuropathol Exp Neurol. 1999;58(8):832-846.
  46. Robb SA, Muntoni F, Simonds AK. Respiratory management of congenital myasthenic syndromes in childhood: Workshop 8th December 2009, UCL Institute of Neurology, London, UK. Neuromuscul Disord. 2010;20(12):833-838.
  47. Palace J, Beeson D. The congenital myasthenic syndromes. J Neuroimmunol 2008;201–202:2–5.
  48. Palace J, Wiles CM, Newsom-Davis J. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry. 1991;54(12):1069-1072.
  49. Harper CM, Engel AG. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol. 1998;43(4):480-484.
  50. Barrons RW. Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy. 1997;17(6):1220-1232.
  51. Dawkins RL, Christiansen FT, Garlepp MJ. Autoantibodies and HLA antigens in ocular, generalized and penicillamine-induced myasthenia gravis. Ann N Y Acad Sci. 1981;377:372-843.
  52. Merryman P, Jaffe IA. Effect of penicillamine on the proliferative response of human lymphocytes. Proc. Soc. Exp. Biol. Med. 1978;157(1):155-158.
  53. Katz LJ, Lesser RL, Merikangas JR, Silverman JP. Ocular myasthenia gravis after D-penicillamine administration. Br J Ophthalmol. 1989;73(12):1015-1018.
  54. Argov Z, Nicholson L, Fawcett PR, Mastaglia FL, Hall M. Neuromuscular transmission and acetylcholine receptor antibodies in rheumatoid arthritis patients on D-penicillamine. Lancet. 1980;1(8161):203-212.
  55. Adams SL, Mathews J, Grammer LC. Drugs that may exacerbate myasthenia gravis. Ann Emerg Med. 1984;13(7):532-538.
  56. Argov Z, Mastaglia FL. Drug therapy: Disorders of neuromuscular transmission caused by drugs. N Engl J Med. 1979;301(8):409-413.
  57. Keogh MJ, Findlay JM, Leach S, Bowen J. Statin-associated weakness in myasthenia gravis: a case report. J Med Case Rep. 2010;4:61.
  58. Lee AG, Brazis PW. Chronic progressive external ophthalmoplegia. Curr Neurol Neurosci Rep. 2002;2(5):413–417.
  59. Ortube MC, Bhola R, Demer JL. Orbital magnetic resonance imaging of extraocular muscles in chronic progressive external ophthalmoplegia: specific diagnostic findings. J AAPOS. 2006;10(5):414-418.
  60. Vilarinho L, Santorelli FM, Coelho I, Rodrigues L, Maia M, Barata I, et al. The mitochondrial DNA A3243G mutation in Portugal: clinical and molecular studies in 5 families. J Neurol Sci. 1999;163(2):168–174.
  61. Zanssen S, Molnar M, Buse G, Schröder JM. Mitochondrial cytochrome b gene deletion in Kearns-Sayre syndrome associated with a subclinical type of peripheral neuropathy. Clin Neuropathol. 1998;17(6):291-296.
  62. Leigh JR, Zee DS. The neurology of eye movements. 5th ed. Oxford, UK: Oxford University Press; 2015.
  63. Anastasopoulos D, Kimmig H, Mergner T, Psilas K. Abnormalities of ocular motility in myotonic dystrophy. Brain. 1996;119 ( Pt 6):1923-1932.
  64. Feibel JH, Campa JF. Thyrotoxic neuropathy (Basedow’s paraplegia). J Neurol Neurosurg Psychiatry. 1976;39(5):491-497.
  65. Kung AW. Neuromuscular complications of thyrotoxicosis. Clin Endocrinol (Oxf). 2007;67(5):645-650.
  66. Sweatman MC, Chambers L. Disordered oesophageal motility in thyrotoxic myopathy. Postgrad Med J. 1985;61(717):619-620.
  67. Hardiman O, Molloy F, Brett F, Farrell M. Inflammatory myopathy in thyrotoxicosis. Neurology. 1997;48(2):339-341.
  68. kung AW. Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab. 2006;91(7):2490–2495.
  69. Nora NA, Berns AS. Hypokalaemic, hypophosphatemic thyrotoxic periodic paralysis. Am J Kidney Dis. 1989;13(3):247-249.
  70. Sahay BM, Blendis LM, Greene R. Relation between myasthenia gravis and thyroid disease. Br Med J. 1965;1(5437):762-765.
  71. Mappouras DG, Philippou G, Haralambous S, Tzartos SJ, Balafas A, Souvatzoglou A, Lymberi P. Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves’s disease. Clin Exp Immunol. 1995;100(2):336-343.
  72. Lakhal K, Blel Y, Fysekidis M, Mohammedi K, Bouadma L. Concurrent Graves disease thyrotoxicosis and myasthenia gravis: the treatment of the former may dangerously reveal the latter. Anaesthesia. 2008;63(8):876-879.
  73. Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142(1):147-153.
  74. Frame F, Thompson SA, Man TM, Edwards MJ, Rosenzweig I. Psychogenic myasthenia gravis. J Neuropsychiatry Clin Neurosci. 2011 Fall;23(4):E1.
  75. Matsumoto H, Shimizu T, Igeta Y, Hashida H. Psychogenic unilateral ptosis with ipsilateral muscle spasm of orbicular oculi. Acta Med Indones. 2012;44(3):243-245.
  76. Peer Mohamed BA, Patil SG. Psychogenic unilateral pseudoptosis. Pediatr Neurol. 2009;41(5):364-366.
  77. Munts AG, Koehler PJ. How psychogenic is dystonia? Views from past to present. Brain. 2010;133(Pt5):1552-1564.
Scroll to Top
× Chat